[BLT Insight]AI-based medical diagnosis solution in Korea

Views 76


AI-based medical diagnostic solutions are disrupting the medical market. AI technology has emerged across the medical market. Among them, the field leading commercialization and the market is the solution that analyzes medical images (including image data) based on AI. Particularly for image analysis involving subjective evaluations by medical professionals, such as CT, MRI, and X-rays, AI technology is suitable for securing analysis accuracy and objective interpretations. Recognizing this technical potential, companies are actively entering the market.


[Image] Scope of AI technology application in the medical field


AI-based medical diagnostic technology fundamentally applies deep learning medical image analysis technology. Based on a deep learning model trained on medical image (video) data, it interprets the presence of diseases. Specifically, when creating image interpretation algorithms to diagnose the presence of diseases, deep learning architectures (model structures), parameter optimization, and more must be considered. To improve disease diagnosis accuracy, a large amount of data needs to be trained. However, there is currently a limitation where training data is limited to specific diseases, focusing on a few diseases with insufficient data. The goal of the AI-based medical diagnostic solution market is to achieve diagnostic accuracy and versatility in diagnosing various diseases.


[Image] Current status and outlook of the global AI-based medical image analysis market (in billions of dollars)


At this inflection point, Korean companies are actively advancing. Kai Health Co., Ltd. (CEO Lim Hye-ju) has succeeded in attracting investment (Pre-A) due to its recognized AI-based infertility solution technology. Kai Health's AI-based infertility solution is an AI solution that can help infertile couples select the best embryo during in vitro fertilization procedures to increase pregnancy rates. In particular, CEO Lee Hye-jun is a former infertility specialist obstetrician and gynecologist who has developed a high-accuracy algorithm based on extensive clinical experience and data from over 20 hospitals. With this investment, they will conduct domestic clinical trials for medical device certification from the Ministry of Food and Drug Safety while simultaneously expanding to various solutions such as infertility, pregnancy, and contraception.


[Image] KaiHealth's AI-based infertility solution (embryo selection)


Additionally, Medipixel Co., Ltd. (CEO Song Gyo-seok), an AI-based medical solution company, has also succeeded in attracting investment (Series B, 17 billion won) due to its recognized technological capabilities. Medipixel's solution 'MPXA' is an AI solution that automatically finds the areas of blood vessels with stenosis in cardiovascular angiography images and displays the degree of stenosis numerically. This solution fully automates the entire analysis process within 1-2 seconds, assisting doctors in real-time during procedures such as stent placement.


[Image] Medipixel's cardiovascular disease diagnosis solution 'MPXA'


Connecteve  Co., Ltd. (CEO Roh Doo-hyun), a Korean company, is also actively developing AI-based medical analysis technology. Connecteve Co., Ltd. is a company developing X-ray-based surgical robots and is developing an AI-based X-ray analysis solution. Specifically, it is a solution for analyzing X-rays to assist in musculoskeletal interpretations, capable of acquiring and learning human body information. Through this, they expect to achieve a 95% accuracy rate for their artificial joint surgery robots.


[Image] Connecteve Co., Ltd.'s AI-based X-ray joint analysis solution


The BLT Research Center predicts, "The AI-based medical diagnostic solution market is expected to experience dramatic growth. These technological changes will present new opportunities for companies to develop related technologies." They added, "Securing rights to medical image diagnostic technologies is expected to be a good strategy."


As of 2024, BLT Law Firm has been a partner chosen by more than 2,000 innovative startups, supporting IP acquisition and strategy formulation, as well as investment attraction, technology special listing, and other business support utilizing IP to drive corporate growth and success.


'BLT insight' introduces a recently invested technology field every week.

If you have any questions about the Korean market or related to intellectual property rights, please ask your questions via the link below:

www.BLT.kr/contact 

Or, you can inquire by emailing shawn@BLT.kr 


Head Office 1F, 25, Beobwon-ro 3-gil, Seocho-gu, Seoul, 06595 Republic of Korea

Tel : +82-2-514-0104     Fax : +82-70-4855-0102     Email : info@blt.kr


Incheon Office 26F, 165, Convensia-daero (POSCO Tower Building), Yeonsu-gu, Incheon (Stage9 Songdo POSCO Tower)

Tel : +82-32-710-5104     Fax : +82-70-4855-0102     Email : info@blt.kr

ⓒ 2023. BLT Patent & Law Firm All Rights Reserved.

Head Office 1F, 25, Beobwon-ro 3-gil, Seocho-gu, Seoul, 06595 Republic of Korea

Tel : +82-2-514-0104     Fax : +82-70-4855-0102     E : info@blt.kr

Incheon Office 26F, 165, Convensia-daero (POSCO Tower Building), Yeonsu-gu, Incheon (Stage9 Songdo POSCO Tower)

Tel : +82-32-710-5104     Fax : +82-70-4855-0102     Email : info@blt.kr


ⓒ 2023. BLT Patent & Law Firm All Rights Reserved.